Trial Profile

A Fixed Sequence, Open-label Study to Assess the Effect of Multiple Doses of AZD5462 on the Pharmacokinetics of Oral Midazolam (CYP3A4 Probe), Rosuvastatin (OATP1B1/3, BCRP Probe), and Digoxin (P-gp Probe) in Healthy Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 5462 (Primary) ; Digoxin (Primary) ; Midazolam (Primary) ; Rosuvastatin (Primary)
Indications Heart failure
Focus Pharmacokinetics
Sponsors AstraZeneca

10 Oct 2022 Status changed from recruiting to completed.
18 Aug 2022 Planned End Date changed from 6 Sep 2022 to 9 Sep 2022.
18 Aug 2022 Planned primary completion date changed from 6 Sep 2022 to 9 Sep 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com